Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
The clinical trial will be conducted at 19 sites with 10,335 participants across India
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Subscribe To Our Newsletter & Stay Updated
